Search results
Results from the WOW.Com Content Network
A new cell study has shown the common type 2 diabetes medication metformin alters levels of microRNAs that target genes to slow down the growth and multiplication of colorectal cancer cells. The ...
Another meta-analysis of 33 studies involving 61,704 patients found that compared with non-metformin control groups, metformin usage among people with pre-existing cardiovascular conditions is ...
Sterne was the first to try metformin on humans for the treatment of diabetes; he coined the name "Glucophage" (glucose eater) for the medication and published his results in 1957. [155] [162] Metformin became available in the British National Formulary in 1958. It was sold in the UK by a small Aron subsidiary called Rona. [163]
Metformin is a member of the biguanide class, improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
In the United States, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. [5] [6]In the European Union, sitagliptin/metformin is indicated as an adjunct to diet and exercise to improve glycemic control in people with type 2 diabetes; in combination with a sulfonylurea as an adjunct to diet and exercise "in people ...
The type 2 diabetes drug metformin helped slow aging across multiple organs, including the brain, kidneys, and the skin, a study in cynomolgus monkeys has shows.
Empagliflozin/metformin was approved for use in the European Union in May 2015. [5] Empagliflozin/metformin was approved for use in the United States in August 2015. [6] [11] The extended release version was approved for use in the United States in December 2016. [12] [13] Empagliflozin/metformin was approved for use in Australia in May 2020. [2]
For premium support please call: 800-290-4726 more ways to reach us